These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

787 related articles for article (PubMed ID: 31884044)

  • 1. Immune-mediated anti-tumor effects of metformin; targeting metabolic reprogramming of T cells as a new possible mechanism for anti-cancer effects of metformin.
    Bahrambeigi S; Shafiei-Irannejad V
    Biochem Pharmacol; 2020 Apr; 174():113787. PubMed ID: 31884044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting T cell metabolism in the tumor microenvironment: an anti-cancer therapeutic strategy.
    Yin Z; Bai L; Li W; Zeng T; Tian H; Cui J
    J Exp Clin Cancer Res; 2019 Sep; 38(1):403. PubMed ID: 31519198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting PPAR ligands as possible approaches for metabolic reprogramming of T cells in cancer immunotherapy.
    Bahrambeigi S; Molaparast M; Sohrabi F; Seifi L; Faraji A; Fani S; Shafiei-Irannejad V
    Immunol Lett; 2020 Apr; 220():32-37. PubMed ID: 31982460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging role of metabolic reprogramming in tumor immune evasion and immunotherapy.
    Fan C; Zhang S; Gong Z; Li X; Xiang B; Deng H; Zhou M; Li G; Li Y; Xiong W; Zeng Z; Li X
    Sci China Life Sci; 2021 Apr; 64(4):534-547. PubMed ID: 32815067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunometabolism: A new target for improving cancer immunotherapy.
    Guo C; Chen S; Liu W; Ma Y; Li J; Fisher PB; Fang X; Wang XY
    Adv Cancer Res; 2019; 143():195-253. PubMed ID: 31202359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adenosine-mono-phosphate-activated protein kinase-independent effects of metformin in T cells.
    Zarrouk M; Finlay DK; Foretz M; Viollet B; Cantrell DA
    PLoS One; 2014; 9(9):e106710. PubMed ID: 25181053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune-mediated antitumor effect by type 2 diabetes drug, metformin.
    Eikawa S; Nishida M; Mizukami S; Yamazaki C; Nakayama E; Udono H
    Proc Natl Acad Sci U S A; 2015 Feb; 112(6):1809-14. PubMed ID: 25624476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of metformin on immunological markers: Implication in its anti-tumor mechanism.
    Chen GG; Woo PYM; Ng SCP; Wong GKC; Chan DTM; van Hasselt CA; Tong MCF; Poon WS
    Pharmacol Ther; 2020 Sep; 213():107585. PubMed ID: 32473961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T cell metabolic fitness in antitumor immunity.
    Siska PJ; Rathmell JC
    Trends Immunol; 2015 Apr; 36(4):257-64. PubMed ID: 25773310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in the role of AMP-activated protein kinase in metabolic reprogramming of metastatic cancer cells: targeting cellular bioenergetics and biosynthetic pathways for anti-tumor treatment.
    Tyszka-Czochara M; Konieczny P; Majka M
    J Physiol Pharmacol; 2018 Jun; 69(3):. PubMed ID: 30279304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Navigating metabolic pathways to enhance antitumour immunity and immunotherapy.
    Li X; Wenes M; Romero P; Huang SC; Fendt SM; Ho PC
    Nat Rev Clin Oncol; 2019 Jul; 16(7):425-441. PubMed ID: 30914826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting SLC1A5 and SLC3A2/SLC7A5 as a Potential Strategy to Strengthen Anti-Tumor Immunity in the Tumor Microenvironment.
    Nachef M; Ali AK; Almutairi SM; Lee SH
    Front Immunol; 2021; 12():624324. PubMed ID: 33953707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new aspect of an old friend: the beneficial effect of metformin on anti-tumor immunity.
    Kim K; Yang WH; Jung YS; Cha JH
    BMB Rep; 2020 Nov; 53(10):512-520. PubMed ID: 32731915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Harnessing Metabolic Reprogramming to Improve Cancer Immunotherapy.
    Yan L; Tan Y; Chen G; Fan J; Zhang J
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival of the fittest: Cancer challenges T cell metabolism.
    Franchina DG; He F; Brenner D
    Cancer Lett; 2018 Jan; 412():216-223. PubMed ID: 29074426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic Checkpoints: Novel Avenues for Immunotherapy of Cancer.
    Shevchenko I; Bazhin AV
    Front Immunol; 2018; 9():1816. PubMed ID: 30131808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metformin and cancer immunity.
    Ma R; Yi B; Riker AI; Xi Y
    Acta Pharmacol Sin; 2020 Nov; 41(11):1403-1409. PubMed ID: 32868904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cation-selective transporters are critical to the AMPK-mediated antiproliferative effects of metformin in human breast cancer cells.
    Cai H; Zhang Y; Han TK; Everett RS; Thakker DR
    Int J Cancer; 2016 May; 138(9):2281-92. PubMed ID: 26669511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquired resistance to metformin in breast cancer cells triggers transcriptome reprogramming toward a degradome-related metastatic stem-like profile.
    Oliveras-Ferraros C; Vazquez-Martin A; Cuyàs E; Corominas-Faja B; Rodríguez-Gallego E; Fernández-Arroyo S; Martin-Castillo B; Joven J; Menendez JA
    Cell Cycle; 2014; 13(7):1132-44. PubMed ID: 24553122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrating T cell metabolism in cancer immunotherapy.
    Dugnani E; Pasquale V; Bordignon C; Canu A; Piemonti L; Monti P
    Cancer Lett; 2017 Dec; 411():12-18. PubMed ID: 28974448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.